“Causes of death in asthma, COPD and non-respiratory hospitalized patients: a multicentric study”

BMC Pulmonary Medicine

Vanessa Santos⁶  Alicia Padilla-Galo⁴  Aitor Ballaz-Quincoces⁵  Jose Serrano⁷  Rosa Vazquez-Oliva⁸  Carlos Almonacid-Sánchez⁹  Carlos Cabrera-López^1,10  Joan B Soriano²  Vicente Plaza³  Jose Gregorio Soto-Campos¹ 

[1] Unidad de Gestion Clínica de Neumología y Alergia, Hospital de Jerez, C/ Sevilla n° 42; 1° J. C.P, Cádiz 11402, Spain;Programa de Epidemiología e Investigación Clínica, Fundación Caubet-CIMERA, Illes Balears, Spain;Hospital de la Santa Creu i Sant Pau, Barcelona, Spain;Hospital Costa del Sol, Málaga, Spain;Hospital de Galdakao, Vizcaya, Spain;Fundación para la Gestión de la Investigación Biomédica de Cádiz, Cádiz, Spain;Hospital Comarcal de Inca, Palma de Mallorca, Spain;Hospital Infanta Elena, Huelva, Spain;Hospital de Guadalajara, Guadalajara, Spain;Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain

关键词: Cardiovascular diseases.;    Mortality;    Respiratory failure;    COPD;    Asthma;   

Others  :  865465
DOI  :  10.1186/1471-2466-13-73

 received in 2012-11-30, accepted in 2013-12-04,  发布年份 2013

【 摘 要 】

Background

There is limited information on the causes of death in asthma patients.

To determine the causes of death in hospitalized asthmatic patients and to compare with those observed in COPD patients and non-respiratory individuals, with a particular interest in associations with previous cardiovascular disease.

Methods

Retrospective case–control study which analyzed the deaths of all hospitalized patients admitted for any reason during January, April, July and October of 2008 in 13 Spanish centers. Medical records of deceased patients were reviewed, and demographic and clinical data were collected.

Results

A total of 2,826 deaths (mean age 75 years, 56% men) were included in the analysis, of which 82 (2.9%) were of patients with asthma and 283 (10%) with COPD.

The most common causes of death in asthma patients were cardiovascular diseases (29.3%), malignancies (20.7%) and infections (14.6%); in COPD patients they were malignancies (26.5%), acute respiratory failure (25.8%) and cardiovascular diseases (21.6%). Asthma, compared to COPD patients, died significantly less frequently from acute respiratory failure and lung cancer. A multivariate logistic regression analysis failed to associate asthma with cardiovascular deaths.

Conclusions

Cardiovascular disease is the most frequent cause of death among hospitalized asthma patients. The specific causes of death differ between asthma and COPD patients.

【 授权许可】

   
2013 Soto-Campos et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Neffen H, Baena-Cagnani C, Malka S, Sole D, Sepúlveda R, Caraballo L, et al.: Asthma mortality in Latin America. J Investig Allergol Clin Immunol 1997, 7:249-253.
• [2]Haahtela T, Klaukka T, Koskela K, Erhola M, Laitinen LA, On the behalf of the Working Group of the Asthma Programme in Finland 1994–2004: Asthma programme in Finland: a community problem needs community solutions. Thorax 2001, 56:806-814.
• [3]Bellido-Casado J, Plaza V, Bardagí S, Cosano J, López Viña A, Martínez Moragón E, Rodríguez-Trigo G, Picado C, Sanchos J: Disminuye la incidencia de asma de riesgo vital en España? Arch Bronconeumol 2006, 42:522-525.
• [4]López-Campos JL, Cayuela A, Rodríguez-Dominguez S, Vigil E: Temporal trends in asthma mortality over 30 years. J Asthma 2008, 45(7):611-614.
• [5]Sáchez-Bahíllo M, García-Marcos M, Pérez_Fernández V, Martínez Torres AE, Sánchez Solís M: Evolución de la mortalidad por asma en España, 1960–2005. Arch Bronconeumol 2009, 45(3):123-128.
• [6]GINA: Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention NHLBI/WHO Workshop Report; 2009. http://www.ginasthma.com webcite
• [7]Guidelines for the Diagnosis and Management of Asthma. US Department of Health and Human Services. National Institutes of Health. National Heart, Lung and Blood Institute. NIH Publication number 08–5846; 2007. http://www.nhlbi.nih.gov/guidelines webcite
• [8]GEMA: Guía Española para el Manejo del Asma. Arch Bronconeumol 2009, 45(Supl 7):2-35. http://www.gemasma.com webcite
• [9]Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B: Low-dose inhaled corticosteroids and prevention of death from asthma. N Engl J Med 2000, 343:332-336.
• [10]Suissa S, Ernst P: Inhaled corticosteroids: impact on asthma morbidity and mortality. J Allergy Clin Immunol 2001, 107:937-944.
• [11]Murray CJ, López AD: Alternative projections of mortality and disability by cause 1990–2020: global burden of disease study. Lancet 1997, 349:1498-1504.
• [12]Calverley PMA, Anderson JA, Celli BR, et al.: Salmeterol and fluticasone propionate and survival in COPD. N Engl J Med 2007, 356(8):775-789.
• [13]Anthonisen NR, Connett JE, Enright PL, Manfreda J, Lung Health Study Research group: Hospitalization and mortality in the lung health study. Am J Crit Care Med 2002, 166:333-339.
• [14]Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, Zulueta J, Cabrera C, Zagaceta J, Hunninghake G, Celli B, BODE Collaborative Group: Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 186(2):155-161.
• [15]Sin DD, Anthonisen NR, Soriano JB, Agusti AG: Mortality in COPD: role of comorbidities. Eur Respir J 2006, 28:1245-1257.
• [16]Silverstein MD, Reed CE, O’Connell EJ, Melton LJ, O’Fallon WM, Yunginger JW: Longterm survival of a cohort of community residents of asthma. N Engl J Med 1994, 331(23):1537-1541.
• [17]Camargo CA, Barr RG, Chen R, Speizer FE: Prospective study of inhaled corticosteroid use, cardiovascular mortality, and all-cause mortality in asthmatic women. Chest 2008, 134(3):546-551.
• [18]Jørgensen IM, Jensen VB, Bülow S, Dahm TL, Prahl P, Juel K: Asthma mortality in the Danish child population: risk factors and causes of asthma death. Pediatr Pulmonol 2003, 36(2):142-147.
• [19]De Marco R, Locatelli F, Cazzoletti L, Bugianio M, Carosso A, Marinoni A: Incidence of asthma and mortality in a cohort of young adults: a 7-year prospective study. Respir Res 2005, 6:95-104. BioMed Central Full Text
• [20]Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL: Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 2005, 128:2099-2107.
• [21]Thomas M, Price D: Impact of comorbidities on asthma. Expert Rev Clin Immunol 2008, 4(6):731-742.
• [22]Boulet LP: Influence of comorbid conditions on asthma. Eur Respir J 2009, 33(4):897-906.
• [23]de Llano LA P, González FC, Añón OC, Perea MP, Caruncho MV, Villar AB: Relationship between comorbidity and asthma control. Arch Bronconeumol 2010, 46(10):508-513.
• [24]Sin DD, Man SF: Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005, 2(1):8-11.
• [25]Onufrak S, Abramson J, Austin H, Holguin F, McClellan W, Viola Vaccarino L: Relation of adult-onset asthma to coronary heart disease and stroke. Am J Cardiol 2008, 101(9):1247-1252.
• [26]Dogra S, Adern CI, Baker J: The relationship between age of asthma onset and cardiovascular disease in Canadians. J Asthma 2007, 44(10):849-854.
• [27]Schanen JG, Iribarren C, Shanar E, Punjabi NM, Rich SS, Sorlie PD, Folsom AR: Asthma and incident cardiovascular disease: the atherosclerosis risk in communities study. Thorax 2005, 60:633-638.
• [28]Jiménez-Puente A, Perea-Milla E, Rivas-Ruiz F: Distribution and trend of deaths within the hospital environment in Spain during the 1997–2003 period. Rev Esp Salud Publica 2006, 80:377-385.
• [29]GOLD: The Global Initiative for Chronic Obstructive Lung Disease. http://www.goldcopd.org/uploads/users/files/GOLDReport07_Changes.pdf webcite
• [30]Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E: Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008, 300(20):2407-2416.
• [31]Singanayagam A, Chalmers JD, Akram AR, Hill AT: Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia. Eur Respir J 2011, 38:36-41.
• [32]O’Byrne PM, Pedersen S, Carlsson LG, Radner F, Thorén A, Peterson S, Ernst P, Suissa S: Risks of pneumonia in patients with asthma taking inhaled corticosteroids. Am J Respir Crit Care Med 2011, 183(5):589-595.
• [33]Adams RJ, Wilson DH, Taylor AW, Daly A, D´Espaignet ET, Grande ED, Ruffin RE: Coexistent chronic conditions and asthma quality of life: a population-based study. Chest 2006, 129:285-291.
• [34]Weatherall M, Wijesinghe M, Perrin K, Harwood M, Beasley R: Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy. Thorax 2010, 65:39-43.
• [35]Oian FH, Zhang Q, Zhou LF, Liu H, Huang H, Zhang XL, Yin KS: High sensitivity creactive protein: a predictive marker in severe asthma. Respirology 2008, 13(5):664-669.
• [36]Kasayama S, Tanemura M, Koya M, Fujita K, Yamamoto H, Miyatake A: Asthma is a independent risk for elevation of plasma C-reactive protein levels. Clin Chim Acta 2009, 399(1–2):79-82.
• [37]Siafakas NM, Antoniou KM, Tzortzaki EG: Role of angiogenesis and vascular remodeling in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2007, 2(4):453-462.
• [38]Capra V, Thompson MD, Sala A, Cole DE, Folco G, Rovati GE: Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends. Med Res Rev 2007, 27(4):469-527.
• [39]Peter-Golden M, Henderson WR: Leukotrienes. Mechanisms of disease. N Engl J Med 2007, 357:1841-1854.
• [40]Ingelssson E, Yin L, Bäck M: Nationwide cohort study of the leukotriene receptor antogonists montelukast and inicident or recurrent cardiovascular disease. J Allergy Clin Immunol 2012, 129(3):702-707.
• [41]Beuther DA, Sutherland ER: Overweight, obesity, and incident asthma: a meta-analysis of prospective epidemiologic studies. Am J Respir Crit Care 2001, 175:661-666.
• [42]Prosser R, Pharm C, Smith A: The comorbidity burden of treated asthma patient population in British Columbia. Chronic Dis Can 2010, 30:46-55.